The Number 1 Forum for Life Science IP and Regulatory Professionals
This industry premier life science legal event will gather the leading pharmaceutical and biotech professionals for 3 days of practical discussion on the protection of pharmaceutical drugs based on patent and regulatory exclusivities.
Attend this face-to-face industry summit and have candid discussions with the European life science intellectual property and regulatory experts. The event allows you to form commercially important business relationships, whilst forming a life science legal strategy for 2024 and beyond.
Once again, this year’s summit will host the pre-event SPC & PTE Forum 2024, allowing a mixed audience of in-house counsels, private practice members and key regulators to discuss the strategies and updates concerning SPCs and PTEs. Add this to your registration and form a comprehensive exclusivity strategy for 2024.
DOWNLOAD THE 2024 EVENT AGENDA TODAY
Leading In-House Speakers
Highlights for 2024 Include
- A review of the latest decisions regarding the SPC waiver and its impact upon your generic and innovator life science exclusivity strategy.
- Discover the intersection between regulatory and IP law with industry-led sessions on: clinical trials, data exclusivity, a Tecfidera case law review and the Pharmaceutical Strategy for Europe.
- Understand the requirements for patentability within the life sciences industry with panel sessions on patent quality, G2/21, enablement and the PTAB.
- Discuss the ways in which the UPC is impacting your life science strategy with an industry-led session and judges panel.
2024 PARTNERS
PLATINUM PARTNERS
Fish & Richardson
Website: https://www.fr.com/
Few firms have protected more innovative and valuable intellectual property than Fish & Richardson. We work with life sciences companies to protect and maximize the value of their IP so that they may achieve their strategic goals through partnership, licensing, financing, acquisition, and enforcement. The Fish team is comprised of accomplished patent attorneys and agents, many of whom boast Ph.D.s and extensive industry experience. Our clients choose to work with Fish attorneys because of their deep technical backgrounds, their expertise on the latest innovations in the industry, and the breadth of their experience working with life sciences companies of every size and in every field.
Maiwald Intellectual Property
Website: https://www.maiwald.eu/en/
As one of Germany’s largest and best-known firms in the field of intellectual property (IP), providing optimal services to our clients is of paramount importance to us. Our team comprising about 250 people in Munich and Düsseldorf works closely with each other and with foreign associates, always with an eye to the client’s particular needs, regardless of the particular industry or type of company, whether start-up, medium-sized firm or large corporation, in Germany and worldwide. We at Maiwald will do everything to ensure that all your IP matters are handled with competence and commitment.
You can rely on Maiwald’s wide-ranging expertise. We provide a full range of services covering all aspects of IP law. Our highly qualified patent attorneys and attorneys-at-law unite all of the most important skills one would expect of an interdisciplinary team: sound legal knowledge, business proficiency and a broad range of technical and scientific know-how. And, it goes without saying, absolute professionalism, efficiency and close attention to the needs of each individual client. So you may be assured of receiving the best possible advice on all IP-related issues based on our proven competence and industry knowledge.
Pinsent Masons
Website: https://www.pinsentmasons.com/
Pinsent Masons international Life Sciences practice is one of the best in Europe.
Their team, comprising more than 100 sector specialists, many of whom are leading individuals in their field with relevant scientific degrees (some to Ph.D.) and experience, drawn from industry, is dedicated to helping their clients continue to develop cutting-edge strategies that use the law as a business enabler to positively impact their bottom line.
The team acts for businesses globally on complex market shifting transactions; cutting edge R&D collaboration; partnering and licensing deals; the most high profile, business-critical patent and regulatory litigations; and hugely impactful anti-trust investigations and litigations.
Comprising some of the world’s leading life sciences experts, the team works with senior management and in-house legal teams to navigate complex regulatory environments, develop effective risk management strategies, and spot and convert opportunities.
GOLD PARTNERS
Carpmaels & Ransford
Website: https://www.carpmaels.com/
Carpmaels & Ransford LLP is a leader in the European IP market, having driven innovation in the industry for over 200 years. The firm advises clients on all aspects of intellectual property, including drafting, filing and prosecuting patent and trademark applications; drafting and negotiating licence agreements and other commercial IP agreements; advising on the transfer of property rights; assisting clients with patent restoration matters; and conducting enforcement and revocation litigation.
The firm has one of Europe’s largest IP teams serving blue-chip clients across the globe, including Johnson & Johnson, Bristol Myers Squibb, Novartis, Ionis Pharmaceuticals, Mars, Gilead, Raytheon, Regeneron, Takeda, Allergan and Xeros. The firm’s attorneys have considerable technical knowledge, bringing together experience from industry-leading companies, academic research at leading universities and extensive patent expertise in the areas of pharmaceuticals, biotechnology, engineering, tech, chemistry, materials, supplementary protection certificates and information and communication technologies and standards.
Through its fully integrated dispute resolution and transactions teams, the firm is able to provide a holistic service to clients which supports their IP needs from inception to commercialisation. The dispute resolution team, made up of experienced solicitors, barristers and patent attorney litigators, represents clients at all levels of the European Patent Office. The team is also adept at conducting enforcement litigation and revocation actions before the UK Intellectual Property Office and patent, copyright, trademark and other IP litigation in the English courts and the Court of Justice of the European Union, often advising in cases where parallel or related litigation is ongoing in courts across Europe or in the United States.
As a European IP firm with litigators and patent attorneys under one roof, Carpmaels & Ransford is looking forward to offering clients the chance to both obtain UPs using the existing EPO procedure and enforce their patents across Europe in the UPC.
Hoffmann Eitle PartmbB
Website: https://www.hoffmanneitle.com/en
Please visit our website for more information.Schertenleib Avocats
Website: https://schertenleib-avocats.com/en/equipe/denis-schertenleib/
Please visit our website for more information.Simmons & Simmons
Website: https://www.simmons-simmons.com/en/expertise/service/intellectual-property/patents
Our international Patent team seamlessly integrates the specialized expertise of a boutique practice with the extensive service offerings of a major international firm. Recognized in the market for our high-calibre clients and active involvement in leading global patent cases, we stand as a trusted force in the European legal landscape; with offices and well established patent experts in London, Amsterdam, Paris, Munich and Milan and with Pharma & Biotech as one of our firm’s four core sectors.
Leveraging our extensive experience, we adeptly guide clients through specialised procedures, including infringement seizures, preliminary injunctions, patent infringement actions, patent nullification actions, and non-infringement declarations. With over 45 years at the forefront of IP law and practice, our international reputation is anchored in a pre-eminent track record in complex patent litigation (alongside a market-leading IP transactions and regulatory practices). Our comprehensive suite of services offers a "one-stop-shop" for pharma and biotech clients needing advice and strategic partnership on patents and other areas of IP.
Simmons and Simmons has played a pivotal role in the development of the Unified Patent Court (UPC) system. Our partner, Kevin Mooney, is acknowledged as one of the "fathers of the UPC", if not “Mr UPC”. Positioned at the forefront of every aspect of the new system, we don't just advise on the law – we actively shape it.
Sterne Kessler
Website: https://www.sternekessler.com/
Please visit our website for more information.Venable LLP
Website: https://www.venable.com/
Venable LLP is an American Lawyer Global 100 law firm headquartered in Washington, DC that serves as primary counsel to a worldwide clientele of large and mid-sized organizations, nonprofits, and high-net-worth entrepreneurs and individuals. With more than 850 professionals across the country, including California, Delaware, Florida, Illinois, Maryland, New York, Virginia, and Washington, DC, the firm strategically advances its clients' objectives in the U.S. and around the globe. Venable advises clients on a broad range of business and regulatory law, legislative affairs, complex litigation, and the full range of intellectual property disciplines. For more information, please visit www.Venable.com.
Gemini Law
Website: http://www.geminilaw.com/
Gemini attorneys are among the most experienced and successful at helping manufacturers of biopharma products navigate IP barriers to access the U.S. market. Gemini has particular expertise in patent strategy and litigation relating to biosimilar, biobetter, generic and 505(b)(2) products, as well as collateral issues concerning the Hatch Waxman and BPCIA regulatory schemes. Gemini is also very experienced in counseling early-stage biotech companies to optimize patent portfolios and mitigate the risk posed by competitors’ IP, as well as IP issues related to licensing and development transactions. Gemini offers “end to end” counseling on IP issues in support of biopharma product development and launch in the U.S., including:
- Litigation risk mitigation and avoidance
- Patent & trade secret design-around strategies
- Patent portfolio optimization
- Biosimilar (BPCIA) litigation & regulatory strategy
- Hatch Waxman litigation & regulatory strategy
- "Biobetter" & "fast follow-on" product litigation & regulatory strategy
- Pharmaceutical device-related litigation & regulatory strategy
- IP & regulatory issues concerning healthcare AI
- CREATES Act requests & litigation
- Section 1782 discovery requests for use in foreign litigation
- Global coordination of litigation strategy concerning biosimilar, generic and biobetter products
- Patent landscaping and freedom-to-operate opinions
- IP-related licensing, development & manufacturing transactions
- Lobbying and legislative initiatives relating to the BPCIA and Hatch Waxman laws
Clifford Chance
Website: https://www.cliffordchance.com/home.html
Clifford Chance is one of the world’s pre-eminent law firms, with significant depth and range of human and IT resources across five continents. The firm is always striving to exceed the expectations of its clients, which includes banks and other financial institutions, corporates from all the commercial and industrial sectors, governments, regulators, trade bodies and not-for-profit organisations. Providing the highest quality advice and legal insight, Clifford Chance prides itself on its approachable, team-based and tech-savvy way of working.
King & Wood Mallesons
Website: https://www.kwm.com/uk/en/home.html
Please visit our website for more information.Taylor Wessing LLP
Website: https://www.taylorwessing.com/en/about-us
Please visit our website for more information.SOLUTION PARTNERS
RWS
Website: https://www.rws.com/intellectual-property-services/
RWS is the world’s leading provider of technology-enabled language, content management, and intellectual property services. With over 60 years of experience in the IP arena RWS expertise in patent translations, foreign filing and IP research services is unrivalled.
Clients trust RWS to deliver high-quality translations in a format ready for filing, in compliance with national filing formalities and maintaining exactly the same protective scope as the original.
RWS also helps clients simplify and streamline their internal processes, by providing flexible, cost-effective foreign filing and renewals services dramatically reducing the administrative burden associated with EP validations, PCT national phase entries and direct filings.
When it comes to research, RWS offers the most robust intellectual property (IP) researcher services and tools available. From our market leading patent research database, PatBase, to the world’s most comprehensive set of IP search offerings from desk based analysts to crowdsearch.
RWS clients include many of the world's largest filers including 19 of the top 20 applicants at the World Intellectual Property Organization and 16 of the top 20 applicants at the European Patent Office.
Founded in 1958, RWS is headquartered in the UK and publicly listed on AIM, the London Stock Exchange regulated market (RWS.L).
Leading Private Practice Speakers
Become A Partner
Interested in how you can get involved with Life Sciences Strategy Summit on IP & Exclusivity 2024?
Based on your objectives, we can create bespoke packages for you. From presenting your expertise on stage to partnering with us to deliver networking activities. Partner with us in 2024 to showcase your brand and make valuable new connections. Opportunities include thought leadership, branding, and networking.
Discuss your objectives with Duncan Henderson, Commercial Partnerships Director, [email protected]
LIFE SCIENCES PATENT ADVISORY BOARD
Dr. Leslie Fischer
Principal Patent Attorney
Sandoz
Leslie Fischer is a Principal Patent Attorney at Sandoz, who focuses on global IP strategy for biosimilars. Before joining Sandoz, Leslie was a patent attorney at Novartis Pharmaceuticals, where she worked for over a decade developing global patent portfolios for biologicals. Before joining the Novartis group, Leslie was an associate at Fitzpatrick Cella (NY) (now Venable). Leslie holds a J.D. from Rutgers University and a Ph.D. in Biochemistry from Thomas Jefferson University. Her scientific work appears in JCB, JBC, and Osteoarthritis & Cartilage. She speaks frequently at patent-related events and is an adjunct professor at Seton Hall Law School.
Christof Bull
Associate General Patent Counsel
UCB
Mathilde Rauline
Head of Greater Europe Patent Litigation
Sanofi
Mathilde is a European patent attorney, is qualified as a French patent attorney, and is admitted to the Paris bar.
She is head of Greater Europe patent litigation at Sanofi, after having been a patent litigator in private practice (mostly in the pharmaceutical field), and a patent attorney in the industry (Sanofi, Nestlé).
She has extensive experience in pharmaceutical and life-science patent litigation in France, at the EPO, in Europe, and in Eurasia.
Her expertise also comprises contractual matters, settlements, regulatory aspects, and the SPC regulation.
Lorenz Kallenbach
Senior Corporate Patent Counsel (Director)
Merck
Lorenz Kallenbach is a senior corporate patent counsel in the healthcare division of Merck KGaA. He is responsible for defining and executing the IP strategy for innovator projects. Including the assessment of the IP landscape, coordination of worldwide patent litigation, and portfolio development.
Before joining Merck, Lorenz worked in private practice. He is qualified as a German and European patent attorney.
Lorenz studied biochemistry and received a Ph.D. in the field of epigenetics.
Stephan Kutik
Senior Director, Intellectual Property
Genevant Sciences GmbH
Ewan Nettleton
Principal IP Counsel, Oncology Litigation
Novartis Pharma AG
Tessa M. Malamud-Cohen
Director, Patents, Global Intellectual Property
Ferring Pharmaceuticals
Paki Banky
Senior IP Counsel (IP Lead Cell & Gene)
Novartis
Corinna Sundermann
Senior Vice President Intellectual Property
Fresenius Kabi
Frank Landolt
Chief Counsel IP & Legal
Confo Therapeutics
Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.
After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands.
Prior to joining Confo in 2018, Frank worked for fifteen years in Ablynx N.V. (now a wholly owned Sanofi company), where he was a member of the management team and headed an integrated IP and legal group of four lawyers and five patent professionals. At Ablynx, Frank was involved in negotiating Ablynx’s strategic partnerships and licensing deals with AbbVie, Boehringer-Ingelheim, MSD, Merck-Serono, Novartis, Novo Nordisk, Sanofi and Wyeth.
From 2000 to 2004, Frank was director of IP and legal counsel at Devgen N.V. (now part of Syngenta), another Ghent-based biotechnology company, where he was involved in negotiating Devgen’s strategic collaborations with Sumitomo, Monsanto and DuPont Pioneer.
Frank is a Dutch and European patent attorney, and also holds a degree in business law from the University of Antwerp. He is a member of the Dutch association of patent attorneys (where he is a tutor for the professional qualification course), EPI and LES Benelux (where he is involved in the LES Licensing Course). He is a regular speaker on a range of topics relating to IP and licensing in the (bio)pharmaceutical sector. Frank was named as one of Managing IP’s ‘Corporate IP stars’ for four years in a row (2015-2018).
Guido Pontremoli
Coporate IP Patent Director
Chiesi
Currently employed as global Head of the IP department-Patent at Chiesi Farmaceutici SpA, managing and coaching a team of experienced patent attorneys, patent searchers and administrators, working on the protection, enforcement, litigation and/or opposition of the Chiesi IP, aligned with business decisions.
Before joining Chiesi, I worked in IP groups of big pharma companies (GSK Vaccine, and Bracco Imaging) as senior patent attorney responsible for all the IP aspects concerning some key R&D projects. I also had experience as patent counsel in private practices, dealing with pharma, chemical and bio entities.
Graduated in chemistry from the Univ of Milan, with a PhD in medicinal chemistry and a post-doc experience in USA, I am qualified EPA and chartered Italian patent attorney.
Kristin Cooklin
Group Head IP Counsel
Recordati
Toni Santamaria
Vice President Intellectual Property
Adalvo
Toni has been leading the Intellectual Property team at Adalvo since 2021. He has more than 20 years of experience in different pharmaceutical companies where he has been involved in developing and implementing complex patent and data exclusivity litigation strategies for several generics and added value products, including leading parallel litigation cases in multiple European countries. He also has experience in patent and trademark prosecution.
Toni qualified as European Patent Attorney in 2010 and holds a PhD in Organic Chemistry.
Shohta Ueno
Assistant General Counsel - Dispute Resolution
Regeneron
Adrian Spillmann
Director of Intellectual Property
Valneva
Julia Pike
Global Head of IP
Sandoz
Since March 2020, Julia has been the Global Head of IP for Sandoz. In her previous roles with Sandoz, she has had a leading role in the first wave of US biosimilars litigation, including the first litigations on critical aspects of the governing legislation (the Biologics Price Competition and Innovation Act or BPCIA), culminating in the landmark US Supreme Court decision, Sandoz v Amgen.
Since leaving private practice at Corrs Chambers Westgarth, Julia has been in-house counsel for many years including at Mayne Pharma and Hospira Inc before joining Sandoz in 2008. While there, she has taken on roles in European public affairs and led Sandoz’s global IP litigation function as Global Head of IP Litigation. Through those roles, she has maintained a keen interest in IP strategy and litigation worldwide, including cases arising under the Hatch-Waxman and BPCIA legislation in the US, PM(NOC) regulations in Canada and litigation arising from patent linkage systems around the world.
Christoph Rehfuess
Head of IP
Sotio
Philip Caramanica
Chief IP Counsel & Deputy General Counsel
Alvotech
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.